Relationships of hepatic and pancreatic biomarkers with the cholestatic syndrome and tumor stage in pancreatic cancer

References

• Armitage P, Berry G, Matthews JNS. (2002). Statistical methods in medical research. 4th edition. Oxford: Blackwell.
   Google Scholar
• Björnsson E, Gustafsson J, Borkman J, Kilander A. (2008). Fate of patients with obstructive jaundice. J Hosp Med 3:117–123.
   PubMedGoogle Scholar
• Crous-Bou M. (2009). Clinical and environmental influences on the prevalence of mutations in the Kras oncogene in patients with pancreatic ductal adenocarcinoma [Doctoral dissertation]. Barcelona: Universitat Autònoma de Barcelona. In Catalan & English. Available at: http://www.imim.es/programesrecerca/epidemiologia/en_documentsgrecm.html
   Google Scholar
• Crous-Bou M, Porta M, Morales E, López T, Carrato A, Puigdomènech E, Real FX; PANKRAS II Study Group. (2009). Past medical conditions and K-ras mutations in pancreatic ductal adenocarcinoma: a hypothesis-generating study. Cancer Causes Control 20:591–599.
   PubMedGoogle Scholar
• Gallo V, Egger M, McCormack V, Farmer PB, Ioannidis JP, Kirsch-Volders M, Matullo G, Phillips DH, Schoket B, Stromberg U, Vermeulen R, Wild C, Porta M, Vineis P; STROBE Statement. (2011). STrengthening the Reporting of OBservational studies in Epidemiology–Molecular Epidemiology (STROBE-ME): an extension of the STROBE Statement. PLoS Med 8:e1001117.
   Google Scholar
• Gama R, Teale JD, Marks V. (2003). Best practice No 173: clinical and laboratory investigation of adult spontaneous hypoglycaemia. J Clin Pathol 56:641–646.
   PubMedGoogle Scholar
• Hung FC, Kuo CM, Chuah SK, Kuo CH, Chen YS, Lu SN, Chang Chien CS. (2007). Clinical analysis of primary duodenal adenocarcinoma: an 11-year experience. J Gastroenterol Hepatol 22:724–728.
   PubMedGoogle Scholar
• Johansen D, Borgström A, Lindkvist B, Manjer J. (2009). Different markers of alcohol consumption, smoking and body mass index in relation to risk of pancreatic cancer. A prospective cohort study within the Malmö Preventive Project. Pancreatology 9:677–686.
   PubMedGoogle Scholar
• Kahan L, Go VL, Larson FC. (1981). Increased activity in serum of an alkaline phosphatase isoenzyme in cancer: analytical method and preliminary clinical studies. Clin Chem 27:104–107.
   PubMedGoogle Scholar
• Lee DH, Jacobs DR Jr. (2006). Association between serum concentrations of persistent organic pollutants and gamma glutamyltransferase: results from the National Health and Examination Survey 1999-2002. Clin Chem 52:1825–1827.
   PubMed Web of Science ®Google Scholar
• Lee DH, Jacobs DR Jr. (2009). Serum gamma-glutamyltransferase: new insights about an old enzyme. J Epidemiol Community Health 63:884–886.
   PubMedGoogle Scholar
• Li D, Jiao L. (2005). Epidemiology.. In: von Hoff DD, Evans DB, Hruban RH, editors. Pancreatic Cancer. Boston: Jones & Bartlett, 103–117.
   Google Scholar
• Löhr JM, Heinemann V, Friess H, eds. (2005). Pancreatic cancer. Bremen: Uni-Med International, 60–63.
   Google Scholar
• Lumbreras B, Porta M, Márquez S, Pollán M, Parker LA, Hernández-Aguado I. (2008). QUADOMICS: an adaptation of the Quality Assessment of Diagnostic Accuracy Assessment (QUADAS) for the evaluation of the methodological quality of studies on the diagnostic accuracy of ‘-omics’-based technologies. Clin Biochem 41:1316–1325.
   PubMed Web of Science ®Google Scholar
• Lumbreras B, Porta M, Márquez S, Pollán M, Parker LA, Hernández-Aguado I. (2009). Sources of error and its control in studies on the diagnostic accuracy of ‘-omics’ technologies. Proteomics Clin Appl 3:173–184.
   PubMed Web of Science ®Google Scholar
• Parker LA, Gómez Saez N, Lumbreras B, Porta M, Hernández-Aguado I. (2010). Methodological deficits in diagnostic research using ‘-omics’ technologies: evaluation of the QUADOMICS tool and quality of recently published studies. PLoS ONE 5:e11419.
   Web of Science ®Google Scholar
• Parker LA, Porta M, Lumbreras B, López T, Guarner L, Hernández-Aguado I, Carrato A, Corominas JM, Rifà J, Fernandez E, Alguacil J, Malats N, Real FX. (2011). Clinical validity of detecting K-ras mutations for the diagnosis of exocrine pancreatic cancer: a prospective study in a clinically-relevant spectrum of patients. Eur J Epidemiol 26:229–236.
   PubMedGoogle Scholar
• Porta M, Alvarez-Dardet C. (1998). Epidemiology: bridges over (and across) roaring levels. J Epidemiol Community Health 52:605.
   PubMedGoogle Scholar
• Porta M, Malats N, Belloc J, Gallén M, Fernandez E. (1996). Do we believe what patients say about their neoplastic symptoms? An analysis of factors that influence the interviewer’s judgement. Eur J Epidemiol 12:553–562.
   PubMedGoogle Scholar
• Porta M, Malats N, Jariod M, Grimalt JO, Rifà J, Carrato A, Guarner L, Salas A, Santiago-Silva M, Corominas JM, Andreu M, Real FX. (1999). Serum concentrations of organochlorine compounds and K-ras mutations in exocrine pancreatic cancer. PANKRAS II Study Group. Lancet 354:2125–2129.
   PubMed Web of Science ®Google Scholar
• Porta M, Costafreda S, Malats N, Guarner L, Soler M, Gubern JM, García-Olivares E, Andreu M, Salas A, Corominas JM, Alguacil J, Carrato A, Rifà J, Real FX. (2000). Validity of the hospital discharge diagnosis in epidemiologic studies of biliopancreatic pathology. PANKRAS II Study Group. Eur J Epidemiol 16:533–541.
   PubMedGoogle Scholar
• Porta M. (2001). Role of organochlorine compounds in the etiology of pancreatic cancer: a proposal to develop methodological standards. Epidemiology 12:272–276.
   PubMedGoogle Scholar
• Porta M, Fernandez E, Alguacil J. (2003). Semiology, proteomics, and the early detection of symptomatic cancer. J Clin Epidemiol 56:815–819.
   PubMedGoogle Scholar
• Porta M, Fabregat X, Malats N, Guarner L, Carrato A, de Miguel A, Ruiz L, Jariod M, Costafreda S, Coll S, Alguacil J, Corominas JM, Solà R, Salas A, Real FX. (2005). Exocrine pancreatic cancer: symptoms at presentation and their relation to tumour site and stage. Clin Transl Oncol 7:189–197.
   PubMedGoogle Scholar
• Porta M, Grimalt JO, Jariod M, Ruiz L, Marco E, López T, Malats N, Puigdomènech E, Zumeta E; PANKRAS II Study Group. (2007a). The influence of lipid and lifestyle factors upon correlations between highly prevalent organochlorine compounds in patients with exocrine pancreatic cancer. Environ Int 33:946–954.
   PubMed Web of Science ®Google Scholar
• Porta M, Pumarega J, Ferrer-Armengou O, López T, Alguacil J, Malats N, Fernàndez E; PANKRAS II Study Group. (2007b). Timing of blood extraction in epidemiologic and proteomic studies: results and proposals from the PANKRAS II Study. Eur J Epidemiol 22:577–588.
   PubMedGoogle Scholar
• Porta M, Ferrer-Armengou O, Pumarega J, López T, Crous-Bou M, Alguacil J, Fitó M, Jariod M, Vicente A, Morales E, Covas MI, Puigdomènech E, Gupta N; PANKRAS II Study Group. (2008). Exocrine pancreatic cancer clinical factors were related to timing of blood extraction and influenced serum concentrations of lipids. J Clin Epidemiol 61:695–704.
   PubMedGoogle Scholar
• Porta M, Pumarega J, López T, Jariod M, Marco E, Grimalt JO; PANKRAS II Study Group. (2009). Influence of tumor stage, symptoms, and time of blood draw on serum concentrations of organochlorine compounds in exocrine pancreatic cancer. Cancer Causes Control 20:1893–1906.
   PubMedGoogle Scholar
• Porta M, Gasull M, Pumarega J. (2012). A step towards more comprehensive analyses of life-course effects of mixtures of environmental factors. Int J Epidemiol. doi: 10.1093/ije/dys014
   PubMedGoogle Scholar
• Sala M, Sunyer J, Herrero C, To-Figueras J, Grimalt J. (2001). Association between serum concentrations of hexachlorobenzene and polychlorobiphenyls with thyroid hormone and liver enzymes in a sample of the general population. Occup Environ Med 58:172–177.
   PubMed Web of Science ®Google Scholar